| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
WORK Medical Technology Group LTD$2.22
-0.02 (-0.89%)
Market Cap
136.52 K
EPS
-102.30
P/E Ratio
-
Value Trade
21.42 M
-89.44 %
Week
-90.48 %
1 Month
-92.12 %
3 Month
-99.97 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
250.13 K
52 Week Range
0.11 - 10,800
% held by Insiders
0.06 %
% held by Institutions
-
Enterprise Value
5.30 M
Total Shares
1.62 M
Short %
26.36 %
Float Shares
1.62 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in WOK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
WORK Medical Technology Group LTD (WOK) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
WOK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
WOK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
WOK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
WOK Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
WOK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
WOKWORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026
WORK Medical Technology Group LTD has announced a 1-for-100 reverse stock split effective June 18, 2026. This move aims to consolidate shares and potentially enhance the stock's market value. After the split, approximately 2.42 million Class A ordinary shares will be outstanding. The company continues to operate in the medical device sector with a diverse product range.
Read more →WOKWORK Medical Technology Group Participated in 2026 CBA-China Annual Conference
WORK Medical Technology Group participated as a partner and exhibitor at the 2026 CBA-China Annual Conference, which took place from May 8 to 10 in Wuxi, Jiangsu Province. The conference brought together experts from the global biopharmaceutical sector to discuss key topics like AI applications in life sciences and global supply chain collaboration. WORK Medical utilized this opportunity to showcase its medical devices and strategic focus on AI-driven healthcare solutions. The company's engagement at the conference aligns with its strategy to enhance international partnerships and innovation efforts in the healthcare space.
Read more →WOKWORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy
WORK Medical Technology Group has established a U.S. subsidiary, Work Bio Technologies Ltd, to enhance its global expansion and long-term growth strategy. This subsidiary will serve as the primary operational platform in the U.S., improving supply chain management and customer engagement. CEO Mr. Wu Shuang emphasized the significance of this move for accelerating business development and strengthening international partnerships.
Read more →WOKWORK Medical Collaborates with Novabioplus to Unlock Biological Data Value with AI, Advancing the “BioToken” Assetization Model
WORK Medical has partnered with Novabioplus to advance AI-driven healthcare solutions. This collaboration aims to integrate AI algorithms with extensive protein datasets to enhance the development of protein antibody therapeutics. The initiative includes four major projects focused on biomolecular design and aims to create 'BioTokens' for biological assets. This partnership marks a significant step in WORK Medical's evolution toward a digital ecosystem in life sciences.
Read more →WOKWORK Medical Deepens Web3.0 Strategic Layout: Co-authors Asset Tokenization Whitepaper
WORK Medical Technology Group LTD has been awarded a Vice President Unit certificate by the Hong Kong Web3.0 Standardization Association. The company is advancing its Web3.0 strategy through the release of an Asset Tokenization Whitepaper, which aims to establish standards for the integration of medical assets with blockchain technology. This initiative is part of a broader strategy to enhance digital infrastructure in healthcare.
Read more →WOKWORK MEDICAL TECHNOLOGY GROUP LTD (an exempted company with limited liability incorporated in the Cayman Islands) (Nasdaq: WOK) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT  the ann
WORK Medical Technology Group Ltd is scheduled to hold its annual general meeting on February 25, 2026, in Hangzhou, China. Shareholders will have the option to attend in person or virtually via a live webcast. The meeting will address significant resolutions, including a proposed share capital increase and adjustments to the company's memorandum of association. Key director elections and a share consolidation will also be discussed.
Read more →WOKWORK Medical Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026
WORK Medical Technology Group has signed a one-year exclusive distribution agreement with Shanghai Benke Medical to market its AI-Automated Blood Cell Morphology Analyzer in East China. The agreement sets a sales target of RMB 10 million for 2026, aiming to enhance market penetration. The Analyzer, recently approved as a Class II medical device, boasts high imaging speed and classification accuracy.
Read more →WOKWORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer
WORK Medical Technology Group's subsidiary has received manufacturing approval for its AI-automated blood cell morphology analyzer from the Hunan Provincial Medical Products Administration. This Class II medical device is designed to improve the efficiency and accuracy of blood cell analysis, supporting clinicians in diagnosing blood disorders. The device is expected to begin manufacturing in the first half of 2026, marking a significant advancement in the company's product offerings.
Read more →WOKWORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025
WORK Medical Technology Group LTD announced a 1-for-100 reverse stock split effective December 29, 2025, following approval from shareholders and the board. This action is primarily aimed at complying with Nasdaq Marketplace Rule 5550(a)(2) regarding minimum share price maintenance. The reverse stock split will not affect shareholders' percentage ownership, except for adjustments due to rounding up of fractional shares. The company's Class A and B ordinary shares will continue trading under the symbol WOK.
Read more →WOKWORK MEDICAL TECHNOLOGY GROUP LTD UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. dollars, except for otherwise noted) As of
Work Medical Technology Group Ltd has released its unaudited condensed consolidated balance sheets and income statements for the six months ending March 31, 2025. The company reported total assets of $34,713,064, a decrease from $36,250,563 in the prior reporting period. Significant issues highlighted include a net loss of $29,425 during this period and a notable decrease in cash and cash equivalents. Despite a marginal increase in current assets and maintaining substantial revenue from third parties, the overall financial outlook indicates challenges due to increasing liabilities and operational losses.
Read more →WOKWORK Medical Technology Group LTD’s Subsidiary Retains a US$114,000 Service Contract from GemPharmatech Corporation
WORK Medical Technology Group LTD's subsidiary, Neologics Bioscience Inc., has secured a $114,000 service contract with GemPharmatech Corporation. This agreement marks a significant step in WORK Medical's global expansion and diversification strategy, focusing on R&D execution. Neologics will provide various testing services, enhancing its collaboration with industry peers and supporting its growth trajectory.
Read more →WOKWORK Medical Technology Group LTD Announces US$1 Million Equity Investment in Neologics Bioscience
WORK Medical Technology Group LTD has announced a US$1 million equity investment in Neologics Bioscience, acquiring a 10% stake. This partnership aims to leverage Neologics' R&D capabilities alongside WORK Medical's operational strengths to foster innovation in medical technology. The investment will support Neologics' operations and market expansion.
Read more →WOKWORK MEDICAL TECHNOLOGY GROUP LTD (an exempted company with limited liability incorporated in the Cayman Islands) (Nasdaq: WOK) NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the extr
WORK Medical Technology Group Ltd has scheduled an extraordinary general meeting for shareholders on November 7, 2025, at 9:30 a.m. Eastern Time. The meeting will allow shareholders to vote on several key resolutions, including a share consolidation and capital increase. Shareholders of record as of October 15, 2025, are entitled to attend and vote, either in person or virtually. The Board of Directors recommends a vote in favor of the proposed resolutions, highlighting a unified stance on the company's strategic direction.
Read more →WOKWORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective October 21, 2025
WORK Medical Technology Group LTD has announced a 1-for-100 reverse stock split effective October 21, 2025. This decision, approved by shareholders and the board, aims to comply with Nasdaq's minimum bid price requirements. The split will reduce the number of outstanding shares significantly while maintaining shareholder percentages, except for rounding adjustments.
Read more →WOKWORK Medical Technology Group LTD Announces Receipt of Delisting Determination Letter from Nasdaq
WORK Medical Technology Group LTD has received a delisting determination letter from Nasdaq due to its Class A ordinary shares trading below $0.10 for ten consecutive days. The company has until October 16, 2025, to appeal this decision to avoid suspension of trading on October 20, 2025. The company is considering options to regain compliance, including a potential reverse share split.
Read more →WOKWORK Medical Technology Group LTD Granted Additional 180-Day Period to Regain Nasdaq Compliance
WORK Medical Technology Group LTD has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. This follows an initial notice indicating the company's stock had not met the necessary criteria. The company plans to address this issue, potentially through a reverse stock split, to avoid delisting.
Read more →WOKWORK Medical Technology Group LTD Announces Pricing of $2.9 Million Registered Direct Offering
WORK Medical Technology Group LTD has announced a registered direct offering of 38,999,334 Class A ordinary shares at $0.075 per share, aiming to raise approximately $2.9 million. The transaction is set to close around September 26, 2025, pending customary conditions. The offering is part of a shelf registration previously approved by the SEC.
Read more →WOKWORK Medical Technology Group LTD Partners with Hong Kong Web3.0 Standardization Association to Collaborate on Blockchain and RWA Innovations
WORK Medical Technology Group LTD has partnered with the Hong Kong Web3.0 Standardization Association to innovate in the Real-world Asset sector. This strategic cooperation aims to develop blockchain solutions and enhance industry standards. The partnership signifies WORK Medical's commitment to advancing technology and business models in the Web3.0 ecosystem.
Read more →WOKWORK Medical Technology Group LTD Partners with Wuxi Branch of Ruijin Hospital-Shanghai Jiao Tong University School of Medicine to Develop AI-Applications in Healthcare
WORK Medical Technology Group LTD has partnered with the Wuxi Branch of Ruijin Hospital to develop AI applications in healthcare. This strategic cooperation aims to enhance hospital informatization and create a digital knowledge base for intelligent healthcare. The collaboration will leverage Xin Rui Hospital's clinical resources to advance AI-driven medical solutions, potentially transforming healthcare delivery in China.
Read more →WOKWORK Medical Technology Group LTD Announces Closing of Registered Offering
WORK Medical Technology Group LTD has successfully closed a registered offering, raising $5 million through the sale of 10 million ordinary units. The proceeds will be allocated towards upgrading production equipment, enhancing research and development, and improving internal compliance systems. The offering was managed by Univest Securities, LLC and is part of the company's growth strategy.
Read more →WOKWORK Medical Technology Group LTD Announces Pricing of Registered Offering
WORK Medical Technology Group LTD has announced the pricing of a registered offering of 10 million ordinary units at $0.50 each. The offering aims to raise approximately $5 million to upgrade equipment and invest in R&D. Each unit includes shares and warrants, with immediate exercisability for certain warrants. The offering is conducted by Univest Securities, LLC.
Read more →WOKWORK Medical Technology GroUP Ltd
WORK Medical Technology Group Ltd has entered into an underwriting agreement with Univest Securities, LLC to offer 10 million Ordinary Units. Each unit includes a Class A ordinary share and two types of warrants. This move aims to bolster the company's capital position and increase its exposure in the market. The registration statement necessary for this offering has already been declared effective by the U.S. SEC, ensuring compliance with regulatory requirements.
Read more →WOKWORK Medical Technology Group LTD Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
WORK Medical Technology Group LTD has received a notification from Nasdaq indicating that it does not meet the minimum bid price requirement, having a closing bid price below $1.00 for 30 consecutive business days. The company has until October 6, 2025, to remedy this situation by achieving a bid price of at least $1.00 for 10 consecutive business days. Although the notification does not affect the company's listing status at this time, failure to comply may lead to delisting. The company plans to monitor its stock price closely and may consider options like a reverse share split to regain compliance.
Read more →WOKWORK Medical Technology Group LTD Announces Implementation of Dual-Class Share Structure Effective
WORK Medical Technology Group LTD has announced the implementation of a dual-class share structure, effective March 6, 2025. This change is anticipated to strengthen corporate governance by allowing enhanced control for existing shareholders. The company, a supplier of medical devices based in Hangzhou, China, has a portfolio of 21 products, with some registered with the U.S. FDA for market entry. The announcement highlights the company’s growth potential and operational strategies in the medical device sector.
Read more →WOKWORK MEDICAL TECHNOLOGY GROUP LTD (an exempted company with limited liability incorporated in the Cayman Islands) (Nasdaq: WOK) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the annual gene
WORK Medical Technology Group Ltd has announced its Annual General Meeting (AGM) scheduled for February 5, 2025, at 9:30 a.m. ET. The meeting will take place in Hangzhou, China, and will also be accessible to shareholders virtually. Key resolutions include the re-election of several directors and a proposal to increase the company's share capital. Only shareholders on record as of January 7, 2025, will be eligible to attend and vote.
Read more →WOKWORK Medical Technology Group LTD Announces Pricing of Initial Public Offering Hangzhou, China
WORK Medical Technology Group LTD has announced the pricing of its initial public offering (IPO) of 2,000,000 ordinary shares at $4.00 each, aiming to raise around $8 million before costs. The shares are set to trade on the Nasdaq Capital Market starting August 23, 2024, with finalization expected by August 26, 2024. Proceeds from the IPO will be allocated to upgrading production equipment and expanding their product offerings, including medical devices and consumables. The company has received effective registration approval from the SEC for the IPO, paving the way for its public debut.
Read more →Competitive Position
How WOK ranks across every disease it competes inCompetitive Position is a premium feature
See how WOK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial